Phase I/II chemosensitization trial of burixafor in combination with fludarabine and cytarabine in adults with relapsed or refractory acute myeloid leukemia

Trial Profile

Phase I/II chemosensitization trial of burixafor in combination with fludarabine and cytarabine in adults with relapsed or refractory acute myeloid leukemia

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Apr 2015

At a glance

  • Drugs Burixafor (Primary) ; Cytarabine; Fludarabine
  • Indications Stem cell mobilisation
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Mar 2015 New trial record
    • 18 Mar 2015 According to a TaiGen Biotechnology media release, this trial is planned for 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top